Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00252863 | DESOLO - SiT Peri-Launch: A Comparison of Symbicort Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma in Adults | PHASE3 | COMPLETED | 1,600 | — | — | Dec 1, 2004 | May 1, 2006 | Mar 17, 2009 | 169 | Germany |
| Name | Type | Description |
|---|---|---|
| Symbicort, used twice daily (b.i.d) and as needed (prn) | DRUG | - |
| Budesonide Turbuhaler 200 µg | DRUG | - |
| Fluticasone Discus 250 µg | DRUG | - |
| Formoterol Turbuhaler 4.5 µg | DRUG | - |
| Terbutaline Turbuhaler 0.5 mg | DRUG | - |
| Salbutamol pressurized metered dose inhaler (pMDI) 100 µg | DRUG | - |
| Salmeterol Discus 50 µg | DRUG | - |
| Budesonide/Formoterol Turbuhaler 160/4.5 µg | DRUG | - |
| Fluticasone/Salmeterol Discus 250/50 µg | DRUG | - |
| Fluticasone/Salmeterol Discus 500/50 µg | DRUG | - |
| Theophylline 200 mg | DRUG | - |
| Theophylline 300 mg | DRUG | - |
| Singulair 10 mg | DRUG | - |
Inclusion Criteria: * Patients with asthma, either well-controlled on a regular therapy with a combination of long-acting beta-agonists and inhaled corticosteroids or symptomatic on therapy with inhaled corticosteroids alone. Exclusion Criteria: * Any other significant lung disease other than ast...